Gilead Sciences (GILD) Revenue — Quarter Ended Mar 31, 2025
Gilead Sciences reported a sequential decline in revenue for the latest quarter, while year-over-year revenue was nearly flat. Operating cash flow remained healthy during the period.
Key takeaway
Quarter ended Mar 31, 2025 · FY2025 Q1
Gilead Sciences reported a sequential decline in revenue for the latest quarter, while year-over-year revenue was nearly flat. Operating cash flow remained healthy during the period.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$6.7B
Revenue reported for this quarter.
Quarter-over-quarter
-11.9%
Change from the immediately preceding quarter.
Year-over-year
-0.3%
Change from the comparable year-ago quarter.
Trailing four quarters
$28.7B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2024 | $7B | +5.4% |
| Sep 30, 2024 | $7.5B | +7.0% |
| Dec 31, 2024 | $7.6B | +6.4% |
| Mar 31, 2025 | $6.7B | -0.3% |
Revenue performance
Revenue decreased compared to the immediately preceding quarter but was essentially unchanged from the same period last year.
Quarterly comparison
Compared to the prior quarter, revenue fell, and versus the same quarter one year earlier, revenue was essentially flat.
What to watch
The sustainability of operating cash flow generation will be a focus given the sequential revenue decline.